共 147 条
[1]
Wong MMY(2020)Anemia and iron deficiency among chronic kidney disease stages 3-5ND patients in the chronic kidney disease outcomes and practice patterns study: often unmeasured, variably treated Clin Kidney J. 13 613-624
[2]
Tu C(2017)Renal association clinical practice guideline on Anaemia of chronic kidney disease BMC Nephrol. 18 345-10
[3]
Li Y(2020)NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease BMC Nephrol. 21 1-35
[4]
Perlman RL(2021)Improving the safety of intravenous iron treatments for patients with chronic kidney disease Expert Opin Drug Saf. 20 23-29
[5]
Pecoits-Filho R(2021)Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review Drugs Context. 10 1-2273
[6]
Lopes AA(2020)Hypophosphatemia after treatment of Iron deficiency with intravenous ferric Carboxymaltose or Iron Isomaltoside - a systematic review and Meta-analysis Br J Clin Pharmacol. 87 2256-443
[7]
Mikhail A(2018)Randomized trial of intravenous iron-induced hypophosphatemia JCI Insight. 3 e124486-1803
[8]
Brown C(2020)Effects of Iron Isomaltoside vs ferric Carboxymaltose on hypophosphatemia in Iron-deficiency Anemia: two randomized clinical trials JAMA - J Am Med Assoc. 323 432-19
[9]
Williams JA(2013)Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women J Bone Miner Res. 28 1793-2003
[10]
Mathrani V(2020)FGF23 at the crossroads of phosphate, iron economy and erythropoiesis Nat Rev Nephrol. 16 7-3282